NASDAQ:CDTX - Cidara Therapeutics, Inc.
$1.61
 $-0.03
-1.83%
11:45AM EDT
2019-07-22
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. The Company is also developing CD201, its bispecific antimicrobial immunotherapy. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CDTX     avg for
industry  
  avg for
sector  
42 stocks weight:  12. 39   217. 37   399. 45  
42 stocks rank:  3. 55 K 1. 27 K 716. 99  
# analyst opinions:  5. 00   13. 21   13. 71  
mean recommendation:  1. 80   2. 10   2. 04  

quick ratio:  3. 04   5. 49   1. 88  
current ratio:  3. 19   5. 87   2. 36  

target price low:  2. 00   83. 44   114. 90  
target price avg:  2. 04   106. 20   137. 90  
target price high:  1. 00   132. 30   158. 97  
1-yr high:  4. 60   111. 86   142. 57  
last close:  1. 64   86. 79   125. 44  
50-day avg:  1. 73   86. 68   122. 63  
200-day avg:  2. 71   89. 22   121. 38  
1-yr low:  1. 49   69. 78   100. 51  
volume:  25. 57 K 2. 62 M 3. 43 M
50-day avg volume:  143. 47 K 3. 20 M 4. 16 M
200-day avg volume:  112. 13 K 2. 99 M 4. 75 M

1-day return:  -2. 96 % -1. 30 % -0. 99 %
this week return:  -3. 53 % 0. 45 % -0. 20 %
12-wk return:  -28. 70 % 0. 94 % 4. 84 %
52-wk return:  -62. 44 % -1. 30 % 10. 55 %

enterprise value (EV):  -1. 49 M 45. 10 B 122. 38 B
market cap:  43. 69 M 38. 96 B 108. 40 B
EBITDA:  -62. 41 M 4. 20 B 8. 19 B
enterprise multiple (EV/EBITDA):  0. 02   5. 38   11. 93  
total debt:  12. 22 M 10. 90 B 17. 48 B
debt/equity:  27. 86   57. 18   120. 05  
net income (common):  -69. 16 M 2. 07 B 4. 05 B

shares outstanding:  21. 40 M 538. 09 M 1. 24 B
shares:  19. 36 M 548. 00 M 1. 22 B
shares short:  949. 68 K 10. 98 M 11. 87 M
shares short prior month:  852. 17 K 9. 32 M 12. 05 M
short ratio:  5. 21   5. 60   3. 34  
short % of float:  3. 94 % 6. 48 % 2. 64 %
total cash/share:  2. 15   10. 98   9. 19  
total cash:  57. 41 M 5. 93 B 6. 10 B
free cash flow:  -34. 72 M 2. 92 B 4. 55 B
operating cash flow:  -59. 13 M 3. 80 B 5. 78 B

book value:  1. 65   13. 35   27. 45  
price/book:  1. 00   4. 60   8. 78  
operating margins:  0. 00 % -308. 40 % -28. 55 %
EBITDA margins:  0. 00 % 13. 17 % 23. 38 %
profit margins:  0. 00 % 10. 44 % 14. 18 %
gross margins:  0. 00 % 35. 80 % 55. 40 %

1-yr max volatility:  0. 00 % --- ---
1-yr mean volatility:  0. 00 % 1. 66 % 1. 03 %

1-yr EPS:  -2. 58   2. 10   4. 23  
forward EPS:  -2. 08   3. 45   7. 10  
P/E:  -0. 64   1. 90   32. 10  
forward P/E:  -0. 79   6. 46   15. 47  
PE/G:  0. 01   0. 70   -0. 54  
growth:  -53. 29 % 265. 63 % 79. 11 %
earnings high:  -0. 36   0. 89   1. 68  
earnings avg:  -0. 56   0. 70   1. 57  
earnings low:  -0. 65   0. 46   1. 46  
revenue high:  -0. 00   2. 57 B 11. 07 B
revenue avg:  -0. 00   2. 51 B 10. 91 B
revenue low:  -0. 00   2. 45 B 10. 73 B
return on assets:  -58. 41 % -2. 34 % 5. 28 %
return on equity:  -124. 13 % -90. 08 % 133. 53 %

beta (1yr vs S&P500):  1. 03   1. 27   0. 91  
sharpe (1yr):  -1. 29   0. 16   0. 77  

held % insiders:  2. 12 % 6. 06 % 3. 29 %
held % institutions:  72. 66 % 78. 22 % 69. 37 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-21 : CDTX
.    101.171 =       101.171 :: --> INITIAL WEIGHT <--
.    - 2.575 =        98.596 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 1.961 =       193.304 :: P/E factor
.    x 2.209 =         427.0 :: PE/G factor
.     x 1.66 =       708.962 :: beta factor
.    x 0.853 =       604.966 :: sharpe factor
.    x 2.544 =      1538.809 :: current ratio factor
.    x 1.221 =      1878.783 :: quick ratio factor
.    x 1.092 =      2051.179 :: short ratio factor
.    x 1.005 =      2061.372 :: price-to-book factor
.    x 4.562 =      9403.959 :: EBITDA factor
.    x 1.002 =      9424.905 :: EBITDA vs industry factor
.     x 1.22 =     11494.146 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.121 =     24376.704 :: sector+industry 1-year gains factor
.    x 1.009 =     24606.529 :: industry 12-weeks return factor
.    x 1.308 =     32182.599 :: industry 2-weeks return factor
.    x 0.971 =     31239.692 :: "drift" penalty 1 days ago
.    x 0.985 =     30778.396 :: "drift" penalty 3 days ago
.    x 0.979 =     30137.843 :: "drift" penalty 5 days ago
.    / 2.026 =     14872.646 :: overall "drift" factor
.    x 0.814 =       12112.0 :: largest single-day jump factor
.    x 0.064 =       779.408 :: low price factor
.    x 0.711 =       554.202 :: notable returns + performance factor
.                               --> PROJECTIONS <--
.    x 0.792 =        438.96 :: forward EPS factor
.    x 0.924 =       405.792 :: forward P/E factor
.    x 1.185 =       480.747 :: industry recommendation factor
.    x 2.389 =      1148.476 :: company recommendation factor
.    x 1.003 =      1151.652 :: factor historical industry gain for week 29
.    x 8.845 =     10186.884 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =        10.046 :: reduced for readability
.    + 2.339 =        12.386 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                     12.386 :: FINAL WEIGHT for NASDAQ:CDTX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org